by Matthias Burel | Dec 12, 2023 | White Papers
Corsano CardioWatch Impact Framework This study’s objective is to assess the societal impact of the Corsano CardioWatch, which provides a non-invasive way of ambulatory blood pressure monitoring (ABPM), replacing more traditional, less precise, and uncomfortable...
by Matthias Burel | Dec 12, 2023 | Insights
Certified Software Corsano has medically certified it’s new software platform under ISO 13485 and EU-MDR. Latest technologies have been applied and the Software Development Process has been meticulously documented for CE-MDR and FDA Certification. Willem...
by Matthias Burel | Dec 12, 2023 | Insights
PPG Accuracy The accuracy of Corsano CardioWatch 287 with pulse detection using photoplethysmography technology in cardiac patients was studied by S. Blok [1,2], M.A. Piek [1], I.I. Tulevski [1], G.A. Somsen [1], M.M. Winter [1,3]. In this single-centre prospective...
by Matthias Burel | Dec 11, 2023 | News
Corsano Health CardioWatch 287-2 EU-MDR Certified Corsano Health is launching the company’s second-generation EU-MDR wearable device that accurately measures eight vital parameters and makes raw PPG and ACC data available for further analysis by third party medical...
by Matthias Burel | Nov 8, 2023 | Clinical Trials
TopicPatients with a suprasellar (hypothalamic) brain tumour often have excellent survival, but poor outcome due to hypothalamic dysfunction (HD). The hypothalamus is an endocrine gland and the key-regulator of our body. It not only regulates the anterior pituitary...
